AI-Generated Drug Rentosertib Shows Early Signs of Reducing Biological Age

Insilico Medicine has released new findings from a clinical trial indicating that its artificial‑intelligence‑designed compound, rentosertib, may lower biological‑age markers in patients. The data, drawn from the same study that previously demonstrated improvements in idiopathic pulmonary fibrosis (IPF), suggest a broader anti‑aging effect.

In a subset of the 43 IPF participants, six independent “aging clocks”—AI models that estimate age from cellular and organ‑function data—showed a statistically significant reduction in predicted biological age after 12 weeks of treatment. This marks the first time a drug has clearly demonstrated a decrease in biological age across multiple clock algorithms.

The trial was originally designed to assess rentosertib’s efficacy against IPF, a condition that rapidly stiffens lung tissue. Early results published last year confirmed that the drug could increase lung capacity in IPF patients. The newer analysis expands the therapeutic ambition, indicating the compound may also influence systemic aging processes.

Experts caution that the study’s scope is limited. “This drug looks encouraging,” said cardiologist Eric Topol, “but we do not yet have a definitive trial to make the final judgment.” Harvard professor Vadim Gladyshev, who helped develop one of the aging clocks, noted that the sample size is small and that the results were obtained only in patients with a specific disease, not in healthy volunteers. “These are methods we will use in future trials,” added Evelyne Bischof of Tel Aviv University, a longevity specialist, highlighting the study’s role as a proof‑of‑concept for AI‑driven anti‑aging research.

Insilico’s approach leverages neural‑network models similar to those powering large language models. The company first trained a system on vast health‑record datasets to pinpoint disease‑related proteins, then built a second model to generate novel molecules that can bind to those targets. This “scan the lock, generate the key” methodology produced rentosertib, initially intended for IPF but now being explored for broader longevity applications.

While the findings represent a milestone for AI in drug discovery, regulatory approval remains years away. Larger, longer‑term trials—including studies in healthy populations—are needed to confirm efficacy, safety, and the clinical relevance of reduced biological age. The study, published in *Nature Biotechnology*, underscores both the promise and the challenges of using AI‑derived aging clocks to accelerate the development of therapies aimed at extending healthy lifespan.

Source link